Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748819 | 1.00 | BACE1 (0.45) | BACE1HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL17675567 | 0.91 | BACE1 (0.43) | BACE1 | |
| SCHEMBL17675384 | 0.84 | BACE1 (0.45) | BACE1HTR2AHTR2CHTR2B | |
| SCHEMBL17088024 | 0.84 | BACE1 (0.45) | BACE1HTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL15357673 | 0.84 | BACE1 (0.45) | BACE1HTR2AHTR2CHTR2B | |
| SCHEMBL19514273 | 0.84 | BACE1 (0.47) | BACE1 | |
| SCHEMBL19514233 | 0.84 | BACE1 (0.47) | BACE1 | |
| SCHEMBL19534477 | 0.81 | BACE1 (0.43) | BACE1 | |
| SCHEMBL1465861 | 0.78 | BACE1 (0.45) | BACE1 | |
| SCHEMBL1465862 | 0.78 | BACE1 (0.45) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885HTR2A 645/4885HTR2C 1643/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | BACE1 1/4885HTR2A 645/4885HTR2C 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.